Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
or

Axsome Thera (AXSM)

Axsome Thera (AXSM)
81.05 x 2 99.90 x 3
Pre-market by (Cboe BZX)
95.65 -6.02 (-5.92%) 04/10/25 [NASDAQ]
81.05 x 2 99.90 x 3
Pre-market 95.65 unch (unch) 16:00 ET
Quote Overview for Thu, Apr 10th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
92.45
Day High
99.57
Open 99.22
Previous Close 101.67 101.67
Volume 1,080,500 1,080,500
Avg Vol 832,925 832,925
Stochastic %K 22.45% 22.45%
Weighted Alpha +19.49 +19.49
5-Day Change -12.24 (-11.34%) -12.24 (-11.34%)
52-Week Range 64.11 - 139.13 64.11 - 139.13
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,957,937
  • Shares Outstanding, K 48,765
  • Annual Sales, $ 385,690 K
  • Annual Income, $ -287,220 K
  • EBIT $ -274 M
  • EBITDA $ -264 M
  • 60-Month Beta 0.88
  • Price/Sales 12.33
  • Price/Cash Flow N/A
  • Price/Book 82.92

Options Overview Details

View History
  • Implied Volatility 73.08% ( +11.77%)
  • Historical Volatility 43.63%
  • IV Percentile 83%
  • IV Rank 48.01%
  • IV High 117.66% on 12/23/24
  • IV Low 31.91% on 08/23/24
  • Put/Call Vol Ratio 0.81
  • Today's Volume 1,710
  • Volume Avg (30-Day) 1,336
  • Put/Call OI Ratio 0.75
  • Today's Open Interest 27,766
  • Open Int (30-Day) 24,213

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 18 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -1.25
  • Number of Estimates 10
  • High Estimate -0.81
  • Low Estimate -1.63
  • Prior Year -1.09
  • Growth Rate Est. (year over year) -14.68%

Price Performance

See More
Period Period Low Period High Performance
1-Month
86.99 +9.96%
on 04/09/25
Period Open: 118.78
130.20 -26.54%
on 03/25/25
-23.13 (-19.47%)
since 03/10/25
3-Month
80.98 +18.11%
on 01/13/25
Period Open: 80.05
139.13 -31.25%
on 02/21/25
+15.60 (+19.49%)
since 01/10/25
52-Week
64.11 +49.20%
on 06/11/24
Period Open: 70.97
139.13 -31.25%
on 02/21/25
+24.68 (+34.78%)
since 04/10/24

Most Recent Stories

More News
Axsome Therapeutics to Report First Quarter 2025 Financial Results on May 5

AXSM : 95.65 (-5.92%)
Axsome Therapeutics Presents Positive Pivotal Phase 3 Results of the ACCORD-2 Trial of AXS-05 in Alzheimer’s Disease Agitation and the SYMPHONY Trial of AXS-12 in Narcolepsy at the 2025 American Academy of Neurology (AAN) Annual Meeting

AXSM : 95.65 (-5.92%)
AXSM Stock Down on Top-Line Data From Depression Study on Solriamfetol

Axsome Therapeutics AXSM announced top-line data from the phase III PARADIGM study, which evaluated solriamfetol for the treatment of major depressive disorder (MDD) with and without severe excessive daytime...

KRYS : 160.65 (-4.47%)
JAZZ : 102.05 (-7.33%)
DVAX : 10.97 (-8.81%)
AXSM : 95.65 (-5.92%)
Alkermes Begins Idiopathic Hypersomnia Study on ALKS 2680

Alkermes plc ALKS announced that it has initiated the phase II Vibrance-3 study, evaluating the novel, investigational and oral orexin 2 receptor agonist, ALKS 2680, in adults with idiopathic hypersomnia...

KRYS : 160.65 (-4.47%)
JAZZ : 102.05 (-7.33%)
ALKS : 26.59 (-7.71%)
AXSM : 95.65 (-5.92%)
Why Shares of Axsome Therapeutics Slumped Today

Shares of biopharmaceutical company Axsome Therapeutics (NASDAQ: AXSM) had declined 6% at 11 a.m. ET today. The slump comes after the company announced the results of a phase 3 trial of solriamfetol (brand...

NVDA : 107.57 (-5.91%)
AXSM : 95.65 (-5.92%)
Axsome Therapeutics Announces Topline Results of PARADIGM Phase 3 Proof-of-Concept Trial of Solriamfetol in Major Depressive Disorder (MDD) with and without Excessive Daytime Sleepiness (EDS)

AXSM : 95.65 (-5.92%)
Why Pharma and Biotech Stocks Got Thrashed on Tuesday

As ever in the often quick-developing biotech and pharmaceutical sectors on Tuesday, companies posted a mix of positive and negative news. Investors clearly took the latter more to heart, as they traded...

MRK : 77.55 (-5.32%)
REGN : 546.39 (-5.26%)
AMGN : 281.41 (-3.33%)
AXSM : 95.65 (-5.92%)
Axsome Therapeutics Announces FOCUS Phase 3 Trial of Solriamfetol in Adults with Attention Deficit Hyperactivity Disorder (ADHD) Achieves Primary Endpoint

AXSM : 95.65 (-5.92%)
HRMY Down 10.8% in Six Months: How Should You Play the Stock?

Shares of Harmony Biosciences HRMY have lost 10.8% in the past six months compared with the industry’s decline of 9.7%. The stock has also underperformed the S&P 500 index during this timeframe.The stock...

JAZZ : 102.05 (-7.33%)
HRMY : 28.99 (-0.28%)
AXSM : 95.65 (-5.92%)
Will Auvelity & Other Drugs Aid AXSM's Growth Amid Stiff Competition?

Axsome Therapeutics’ AXSM Auvelity (AXS-05) was launched in the United States in 2022 for the treatment of major depressive disorder (MDD), making it the first approved drug in the company’s portfolio.Auvelity...

JAZZ : 102.05 (-7.33%)
ACAD : 14.11 (-5.68%)
AXSM : 95.65 (-5.92%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Axsome Therapeutics is a biopharmaceutical company focused on developing novel therapies for the management of central nervous system (CNS), disorders for which there are limited treatment options available.

See More

Key Turning Points

3rd Resistance Point 106.44
2nd Resistance Point 103.00
1st Resistance Point 99.33
Last Price 95.65
1st Support Level 92.21
2nd Support Level 88.77
3rd Support Level 85.10

See More

52-Week High 139.13
Fibonacci 61.8% 110.47
Fibonacci 50% 101.62
Last Price 95.65
Fibonacci 38.2% 92.77
52-Week Low 64.11

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar